Summary of Study ST002075
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001315. The data can be accessed directly via it's Project DOI: 10.21228/M8R11F This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002075 |
Study Title | Profiling of the human intestinal microbiome and bile acids under physiologic conditions using an ingestible sampling device (Part 2) |
Study Summary | 15 Subjects were sampled using ingestible sampling device. Device sampled regions of the small intestine depending on design of sampling device. |
Institute | University of California, Davis |
Last Name | Folz |
First Name | Jacob |
Address | 451 Health Sciences Drive |
jfolz@ucdavis.edu | |
Phone | (530) 752-8129 |
Submit Date | 2022-02-02 |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Thermo) |
Analysis Type Detail | LC-MS |
Release Date | 2022-12-15 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001315 |
Project DOI: | doi: 10.21228/M8R11F |
Project Title: | Profiling of the human intestinal microbiome and bile acids under physiologic conditions using an ingestible sampling device |
Project Summary: | 15 human subjects were sampled using ingestible sampling device to sample different regions of the small intestine using different types of capsules (Capsule Type 1 to 4). Stool was also analyzed. |
Institute: | University of California, Davis |
Last Name: | Folz |
First Name: | Jacob |
Address: | 451 Health Sciences Drive |
Email: | jfolz@ucdavis.edu |
Phone: | (530) 752-8129 |
Subject:
Subject ID: | SU002158 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Gender: | Male and female |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Treatment |
---|---|---|
SA195958 | 1978 | Capsule Type 1 |
SA195959 | 1546 | Capsule Type 1 |
SA195960 | 1475 | Capsule Type 1 |
SA195961 | 1550 | Capsule Type 1 |
SA195962 | 1479 | Capsule Type 1 |
SA195963 | 1936 | Capsule Type 1 |
SA195964 | 1486 | Capsule Type 1 |
SA195965 | 1973 | Capsule Type 1 |
SA195966 | 1542 | Capsule Type 1 |
SA195967 | 1470 | Capsule Type 1 |
SA195968 | 1932 | Capsule Type 1 |
SA195969 | 1558 | Capsule Type 1 |
SA195970 | 1458 | Capsule Type 1 |
SA195971 | 1457 | Capsule Type 1 |
SA195972 | 1559 | Capsule Type 1 |
SA195973 | 1988 | Capsule Type 1 |
SA195974 | 1462 | Capsule Type 1 |
SA195975 | 1538 | Capsule Type 1 |
SA195976 | 1466 | Capsule Type 1 |
SA195977 | 1985 | Capsule Type 1 |
SA195978 | 1982 | Capsule Type 1 |
SA195979 | 1970 | Capsule Type 1 |
SA195980 | 1507 | Capsule Type 1 |
SA195981 | 1506 | Capsule Type 1 |
SA195982 | 1526 | Capsule Type 1 |
SA195983 | 1962 | Capsule Type 1 |
SA195984 | 1508 | Capsule Type 1 |
SA195985 | 1957 | Capsule Type 1 |
SA195986 | 1953 | Capsule Type 1 |
SA195987 | 1949 | Capsule Type 1 |
SA195988 | 1522 | Capsule Type 1 |
SA195989 | 1502 | Capsule Type 1 |
SA195990 | 1945 | Capsule Type 1 |
SA195991 | 1494 | Capsule Type 1 |
SA195992 | 1491 | Capsule Type 1 |
SA195993 | 1940 | Capsule Type 1 |
SA195994 | 1533 | Capsule Type 1 |
SA195995 | 1966 | Capsule Type 1 |
SA195996 | 1944 | Capsule Type 1 |
SA195997 | 1530 | Capsule Type 1 |
SA195998 | 1498 | Capsule Type 1 |
SA195999 | 1561 | Capsule Type 1 |
SA196000 | 1929 | Capsule Type 1 |
SA196001 | 1920 | Capsule Type 1 |
SA196002 | 1909 | Capsule Type 1 |
SA196003 | 2011 | Capsule Type 1 |
SA196004 | 1425 | Capsule Type 1 |
SA196005 | 1906 | Capsule Type 1 |
SA196006 | 2008 | Capsule Type 1 |
SA196007 | 1437 | Capsule Type 1 |
SA196008 | 1436 | Capsule Type 1 |
SA196009 | 1435 | Capsule Type 1 |
SA196010 | 1917 | Capsule Type 1 |
SA196011 | 2014 | Capsule Type 1 |
SA196012 | 1417 | Capsule Type 1 |
SA196013 | 2017 | Capsule Type 1 |
SA196014 | 1414 | Capsule Type 1 |
SA196015 | 1413 | Capsule Type 1 |
SA196016 | 1418 | Capsule Type 1 |
SA196017 | 1914 | Capsule Type 1 |
SA196018 | 1422 | Capsule Type 1 |
SA196019 | 2015 | Capsule Type 1 |
SA196020 | 2016 | Capsule Type 1 |
SA196021 | 2005 | Capsule Type 1 |
SA196022 | 1434 | Capsule Type 1 |
SA196023 | 1898 | Capsule Type 1 |
SA196024 | 1897 | Capsule Type 1 |
SA196025 | 2001 | Capsule Type 1 |
SA196026 | 1442 | Capsule Type 1 |
SA196027 | 1993 | Capsule Type 1 |
SA196028 | 1902 | Capsule Type 1 |
SA196029 | 1924 | Capsule Type 1 |
SA196030 | 1997 | Capsule Type 1 |
SA196031 | 1450 | Capsule Type 1 |
SA196032 | 1446 | Capsule Type 1 |
SA196033 | 1518 | Capsule Type 2 |
SA196034 | 1555 | Capsule Type 2 |
SA196035 | 1899 | Capsule Type 2 |
SA196036 | 1527 | Capsule Type 2 |
SA196037 | 1946 | Capsule Type 2 |
SA196038 | 1520 | Capsule Type 2 |
SA196039 | 1519 | Capsule Type 2 |
SA196040 | 1915 | Capsule Type 2 |
SA196041 | 1562 | Capsule Type 2 |
SA196042 | 1523 | Capsule Type 2 |
SA196043 | 1557 | Capsule Type 2 |
SA196044 | 1925 | Capsule Type 2 |
SA196045 | 1539 | Capsule Type 2 |
SA196046 | 1933 | Capsule Type 2 |
SA196047 | 1928 | Capsule Type 2 |
SA196048 | 1937 | Capsule Type 2 |
SA196049 | 1543 | Capsule Type 2 |
SA196050 | 1921 | Capsule Type 2 |
SA196051 | 1547 | Capsule Type 2 |
SA196052 | 1537 | Capsule Type 2 |
SA196053 | 1551 | Capsule Type 2 |
SA196054 | 1531 | Capsule Type 2 |
SA196055 | 1903 | Capsule Type 2 |
SA196056 | 1918 | Capsule Type 2 |
SA196057 | 1910 | Capsule Type 2 |
Collection:
Collection ID: | CO002151 |
Collection Summary: | Fifteen healthy subjects were enrolled in this study, and each swallowed 17 devices over the course of three days. All 255 ingested devices were recovered, and no adverse events were reported during the study. Of the 255 ingested devices, 17 contained mainly gas. Ten of the 238 ingested devices that did not contain large amounts of gas provided samples with >0 ng of DNA . Saliva samples were collected after evening meals and immediately frozen. Every bowel movement during the study was immediately frozen by the subject at -20 °C. Subject 1 provided additional samples for assessment of replicability and blooming. |
Sample Type: | Intestine |
Treatment:
Treatment ID: | TR002170 |
Treatment Summary: | The capsule sampling device (CapScan®, Envivo Bio Inc, San Carlos CA) consists of a one-way valve capping a hollow elastic bladder. The device is prepared for packaging by evacuating the elastic bladder, folding it in half, and packaging the folded device inside a dissolvable capsule measuring 6.5 mm in diameter×23 mm long, onto which an enteric coating is applied. The target pH was pH 6 for type 1 and type 2 capsules, and pH 7.5 for type 3 and type 4, with type 2 and type 4 having a thicker coating to result in delayed opening. The elastic bladder then unfolds and expands into a tube 6 mm in diameter and 33 mm long, thereby drawing in ~300 µL of gut luminal contents through the one-way valve. The one-way valve maintains the integrity of the sample collected inside the bladder as the device moves through the colon and is exposed to stool. |
Sample Preparation:
Sampleprep ID: | SP002164 |
Sampleprep Summary: | Supernatants from intestinal samples were extracted using a modified 96-well plate biphasic extraction63. Samples in microcentrifuge tubes were thawed on ice and 10 µL were transferred to wells of a 2-mL polypropylene 96-well plate in a predetermined randomized order. A quality control (QC) sample consisteing of a pool of many intestinal samples from pilot studies was used to assess analytical variation. QC sample matrix (10 µL) and blanks (10 µL of LC-MS grade water) were included for every 10th sample. One hundred seventy microliters of methanol containing UltimateSPLASH Avanti Polar Lipids (Alabaster, Alabama) as an internal standard were added to each well. Then 490 µL of methyl-tert-butyl-ether (MTBE) containing internal standard Cholesterol Ester 22:1 were added to each well. Plates were sealed, vortexed vigorously for 30 s, and shaken on an orbital shaking plate for 5 min at 4 °C. The plate was unsealed and 150 µL of cold water were added to each well. Plates were re-sealed, vortexed vigorously for 30 s, and centrifuged for 12 min at 4000 rcf and 4 °C. From the top phase of the extraction wells, two aliquots of 180 µL each were transferred to new 96-well plates, and two aliquots of 70 µL each from the bottom phase were transferred to two other new 96-well plates. Plates were spun in a rotary vacuum until dry, sealed, and stored at -80 °C until LC-MS/MS analysis. One of the 96-well plates containing the aqueous phase of extract was dissolved in 35 µL of HILIC-run solvent (8:2 acetonitrile/ water, v/v). Five microliters were analyzed using non-targeted HILIC LC-MS/MS analysis. Immediately after HILIC analysis, the 96-well plates were spun in a rotary vacuum until dry, sealed, and stored at -80 °C until targeted bile acid analysis. Approximately 4±1 mg of wet stool were transferred to 2-mL microcentrifuge tubes. Twenty microliters of QC mix were added to microcentrifuge tubes for QC samples. Blank samples were generated using 20 µL of LC-MS grade water. To each tube, 225 µL of ice-cold methanol containing internal standards (as above) were added, followed by 750 µL of ice-cold MTBE with CE 22:1. Two 3-mm stainless-steel grinding beads were added to each tube and tubes were processed in a Geno/Grinder automated tissue homogenizer and cell lyser at 1500 rpm for 1 min. One hundred eighty-eight microliters of cold water were then added to each tube. Tubes were vortexed vigorously and centrifuged at 14,000 rcf for 2 min. Two aliquots of 180 µL each of the MTBE layer and two aliquots of 50 µL each of the lower layer were transferred to four 96-well plates, spun in a rotary vacuum until dry, sealed, and stored at -80 °C until analysis with the intestinal samples. Stool samples were analyzed using HILIC non-targeted LC-MS/MS and diluted in an identical manner to intestinal samples as described above. Stool samples were analyzed in a randomized order after intestinal samples. |
Combined analysis:
Analysis ID | AN003382 |
---|---|
Analysis type | MS |
Chromatography type | HILIC |
Chromatography system | Thermo Vanquish |
Column | Waters Acquity UPLC BEH amide,(150 x 2.1mm,1.7um) |
MS Type | ESI |
MS instrument type | Orbitrap |
MS instrument name | Thermo Q Exactive HF hybrid Orbitrap |
Ion Mode | POSITIVE |
Units | peak height |
Chromatography:
Chromatography ID: | CH002500 |
Chromatography Summary: | Data acquisition : 3 µL sample aliquots were injected on a Waters Acquity UPLC BEH Amide column (150 mm length × 2.1 mm id; 1.7 μm particle size) maintained at 45°C. A Waters Acquity VanGuard BEH Amide pre-column (5 mm × 2.1 mm id; 1.7 μm particle size) was used as guard column. Mobile phase A was 100% LC-MS grade water with 10 mM ammonium formate and 0.125% formic acid and mobile phase B was 95:5 v/v acetonitrile:water with 10 mM ammonium formate and 0.125% formic acid. Gradient was started at 100% (B) for 2 min, 70% (B) at 7.7 min, 40% (B) at 9.5 min, 30% (B) at 10.25 min, 100% (B) at 12.75 min and isocratic until 16.75 min. The column flow was 0.4 mL/min. Vanquish UHPLC system (ThermoFisher Scientific) was used. |
Instrument Name: | Thermo Vanquish |
Column Name: | Waters Acquity UPLC BEH amide,(150 x 2.1mm,1.7um) |
Flow Gradient: | Gradient was started at 100% (B) for 2 min, 70% (B) at 7.7 min, 40% (B) at 9.5 min, 30% (B) at 10.25 min, 100% (B) at 12.75 min and isocratic until 16.75 min. |
Flow Rate: | 0.4 mL/min |
Solvent A: | 100% water; 0.125% formic acid; 10 mM ammonium formate |
Solvent B: | 95% acetonitrile/5% water 0.125% formic acid; 10 mM ammonium formate |
Chromatography Type: | HILIC |
MS:
MS ID: | MS003149 |
Analysis ID: | AN003382 |
Instrument Name: | Thermo Q Exactive HF hybrid Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | A Thermo Q-Exactive HF Orbitrap MS instrument was operated in positive and negative ESI mdoes respectively with the following parameters: mass range 60−900 m/z; spray voltage 3.6kV (ESI+) and −3kV (ESI−), sheath gas (nitrogen) flow rate 60 units; auxiliary gas (nitrogen) flow rate 25 units, capillary temperature 320 ◦C, full scan MS1 mass resolving power 60,000, data-dependent MSMS (dd-MSMS) 4 scans per cycle, normalized collision energy at 20%, 30%, and 40%, dd-MSMS mass resolving power 15,000. Thermo Xcalibur 4.0.27.19 was used for data acquisition and analysis. Instruments was tuned and calibrated by manufacturer’s recommendations. MSDIAL was used for data processing. Conjugated bile acid peak height was converted to relative concentration in ng/mL by comparing to targeted bile acid dataset ST002073. |
Ion Mode: | POSITIVE |